This is a competitive renewal for a project that has been directed at understanding the role of aberrant TGFalpha signaling as a basis for disrupted growth regulation in colon cancer. We have found that TGFalpha is constitutively upregulated in highly malignant colon cancer cells, but is downregulated in Go premalignant and normal cells. This constitutive TGFalpha expression leads to a low, but constitutive activation of the EGFR, ErbB2 and downstream signaling including the PLCgamma, MAPK and PI3K pathways. These pathways generate growth factor independence as reflected by lack of exogenous growth factors for cell cycle re-entry and constitutive cell survival signaling. Colon cancer is one of the histological types of cancer showing a low rate of response to EGFR antagonism in the clinic as several small molecular weight tyrphostin derivatives as well as monoclonal antibodies are in various stages of development. The small molecular weight EGFR antagonists appear to be pan ErbB antagonists as well, but we have found that they fail to inhibit autophosphorylation of Y1248 by activated ErbB2 kinase in EGFR/ErbB2 heteromers. This is important because ErbB2 kinase, EGFR kinase independent signaling is prevalent in colon cancer cells and can lead to the activation of the PI3K or PLCgamma pathways and cell survival signaling. Thus, we have identified novel mechanisms of ErbB2 mediated signal diversification arising from aberrant autocrine TGFalpha which can circumvent the effects of this class of compounds in the clinic. Consequently, it is important to understand this signal diversification in colon cancer in order to optimize combination therapy with EGFR and ErbB2 antagonists.
Specific Aims for the next cycle of the project are: 1. Determine the role of ErbB2 in the specification of essential signaling contributing to the malignant phenotype in colon cancer cells. 2. Determine how repression of ErbB2 dependent kinase signaling affects therapy by EGFR antagonists. 3. Determine mediators of cell survival signaling by ErbB family autocrine activation in colon carcinoma cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA034432-20
Application #
6769395
Study Section
Special Emphasis Panel (ZRG1-ET-2 (01))
Program Officer
Blair, Donald G
Project Start
1982-02-01
Project End
2007-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
20
Fiscal Year
2004
Total Cost
$346,046
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Leiphrakpam, Premila D; Agarwal, Ekta; Mathiesen, Michelle et al. (2014) In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer. Oncol Rep 31:87-94
Leiphrakpam, Premila D; Rajput, Ashwani; Mathiesen, Michelle et al. (2014) Ezrin expression and cell survival regulation in colorectal cancer. Cell Signal 26:868-79
Agarwal, Ekta; Chaudhuri, Anathbandhu; Leiphrakpam, Premila D et al. (2014) Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer. BMC Cancer 14:145
Chowdhury, Sanjib; Ongchin, Melanie; Sharratt, Elizabeth et al. (2013) Intra-tumoral heterogeneity in metastatic potential and survival signaling between iso-clonal HCT116 and HCT116b human colon carcinoma cell lines. PLoS One 8:e60299
Agarwal, Ekta; Brattain, Michael G; Chowdhury, Sanjib (2013) Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal 25:1711-9
Zou, Yi; Howell, Gillian M; Humphrey, Lisa E et al. (2013) Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi). PLoS One 8:e69992
Wang, Jing; Rajput, Ashwani; Kan, Julie L C et al. (2009) Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem 284:10912-22
Sawhney, Rajinder S; Liu, Wensheng; Brattain, Michael G (2009) A novel role of ERK5 in integrin-mediated cell adhesion and motility in cancer cells via Fak signaling. J Cell Physiol 219:152-61
Li, Fengzhi; Brattain, Michael G (2006) Role of the Survivin gene in pathophysiology. Am J Pathol 169:1-11